ICUI · Icu Medical Inc/De
$179.59
-2.65 (-1.45%)
At close · Aug 26
View the 10-Q filed Aug 6, 2026
Customer concentration
— top customer 19% of revenue
One customer — 19% of revenue (the six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”
One customer — 19% of revenue (the three months ended June 30, 2026)
“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”
One customer — 19% of revenue (the three months ended June 30, 2025)
“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”
One customer — 18% of revenue (the six months ended June 30, 2025)
“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”
Market Cap
$4.56B
Shares
25.01M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.23B
-6.3%
FY2025
Net Income
$732K
+100.6%
FY2025
Gross Margin
36.84%
+2.2pp
FY2025
Operating Margin
1.92%
+0.1pp
FY2025
Diluted EPS
$0.03
+100.6%
FY2025
Operating Cash Flow
$179.85M
-11.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $2.16B | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B | $1.27B | $1.27B | $1.4B | $1.29B | $379.37M | $341.67M | $309.26M | $313.72M | $316.87M | $302.2M | $282.96M | $228.97M | $204.73M | $188.14M | |
| — | — | -$83.03M | -$95.75M | -$95.22M | -$66.38M | $1.98M | $1.92M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1.31B | $1.41B | $1.56B | $1.52B | $1.58B | $824.82M | $809.51M | $794.34M | $830.01M | $866.52M | $177.97M | $160.87M | $157.86M | $158.98M | $160.36M | $159.84M | $153.99M | $122.7M | $114.91M | $109.9M | |
| — | $845.15M | $822.04M | $824.78M | $739.87M | $697.76M | $491.49M | $461.5M | $471.86M | $570.03M | $426.1M | $201.4M | $180.8M | $151.4M | $154.73M | $156.51M | $142.35M | $128.97M | $106.28M | $89.82M | $78.24M | |
| — | — | 36.84% | 34.62% | 32.75% | 30.6% | 37.34% | 36.31% | 37.27% | 40.72% | 32.96% | 53.09% | 52.92% | 48.96% | 49.32% | 49.39% | 47.11% | 45.58% | 46.41% | 43.87% | 41.59% | |
| — | $86.32M | $87.5M | $88.62M | $85.34M | $92.98M | $47.5M | $42.95M | $48.61M | $52.87M | $51.25M | $12.96M | $15.71M | $18.33M | $12.41M | $10.63M | $8.59M | $4.68M | $2.65M | $4.82M | $8.11M | |
| — | $615.07M | $625.21M | $638.76M | $606.69M | $608.35M | $302.58M | $283.95M | $276.98M | $320M | $302.17M | $89.43M | $83.22M | $88.94M | $89.01M | $84.6M | $85.29M | $76.64M | $68.21M | $53.61M | $45.48M | |
| — | $132.2M | $131.4M | $134.3M | $132.1M | $139.4M | $23.8M | $23.2M | $17.7M | $16.6M | $15M | $2.8M | $2.2M | $2.4M | $2.5M | $2.6M | $2.7M | $2.8M | $2.3M | — | — | |
| — | — | $200.74M | $219.51M | $228.77M | $235.15M | $89.7M | $85.63M | $76.92M | $74.74M | $66.57M | $19.05M | $18.07M | $19.45M | $19.51M | $19M | $18.29M | $17.35M | $15.67M | $14.22M | $11.8M | |
| — | — | — | — | $5.7M | $9.7M | -$1.8M | $7.9M | $8.4M | $4.5M | $18.8M | $800K | $6.7M | $3.5M | — | — | — | — | — | — | — | |
| — | $773.09M | $779.21M | $781.82M | $717.05M | $740.66M | $368.25M | $363.34M | $364.5M | $540.27M | $439.39M | $118.46M | $112.23M | $112.36M | $102.78M | $95.23M | $77.13M | $81.31M | $70.85M | $58.43M | $53.6M | |
| — | $72.06M | $42.83M | $42.96M | $22.83M | -$42.9M | $123.25M | $98.16M | $107.36M | $29.76M | -$13.29M | $82.94M | $68.57M | $39.04M | $51.95M | $61.28M | $65.22M | $47.66M | $35.43M | $31.38M | $24.65M | |
| — | — | 1.92% | 1.8% | 1.01% | -1.88% | 9.36% | 7.72% | 8.48% | 2.13% | -1.03% | 21.86% | 20.07% | 12.62% | 16.56% | 19.34% | 21.58% | 16.84% | 15.47% | 15.33% | 13.1% | |
| — | — | $243.57M | $262.48M | $251.6M | $192.25M | $212.94M | $183.79M | $184.28M | $104.49M | $53.28M | $101.99M | $86.64M | $58.48M | $71.46M | $80.28M | $83.52M | $65M | $51.1M | $45.6M | $36.44M | |
| — | $83M | $93.34M | $106.54M | $102.73M | $70.81M | $858K | $1.75M | $549K | $709K | $2.05M | $118K | $39K | — | — | — | — | — | — | — | — | |
| — | -$1.58M | -$232K | -$13.22M | -$5.91M | -$5.14M | -$2.04M | -$2.59M | $7.9M | -$6.67M | -$4.27M | $885K | $1.17M | $755K | $765K | $563K | $1.2M | $129K | $1.18M | $4.7M | $8.7M | |
| — | -$1.62M | -$1.19M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $754K | $4.36M | -$66.01M | -$78.3M | — | — | $97.49M | $114.71M | $22.37M | $51.28M | $85.16M | $69.7M | $39.79M | $52.71M | $61.84M | $66.42M | $47.79M | $36.61M | $36.08M | $33.35M | |
| — | -$30.96M | $2.44M | $51.68M | -$48.64M | -$40.12M | $20.05M | $10.62M | $13.67M | -$6.42M | -$17.36M | $22.08M | $24.71M | $13.46M | $12.3M | $20.56M | $21.75M | $17.86M | $11.63M | $11.78M | $10.34M | |
| — | $30.09M | $732K | -$117.69M | -$29.66M | -$74.29M | $103.14M | $86.87M | $101.04M | $28.79M | $68.64M | $63.08M | $44.99M | $26.34M | $40.42M | $41.28M | $44.67M | $29.92M | $24.98M | $24.3M | $23.08M | |
| — | — | 0.03% | -4.94% | -1.31% | -3.26% | 7.84% | 6.83% | 7.98% | 2.06% | 5.31% | 16.63% | 13.17% | 8.52% | 12.88% | 13.03% | 14.78% | 10.58% | 10.91% | 11.87% | 12.27% | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $44.67M | $29.92M | $24.98M | — | -$70K | |
| — | $19.4M | $105.5M | -$204.01M | -$1.76M | -$136M | $85.39M | $100.75M | $102.58M | $26.81M | $74.96M | $62.57M | $33.78M | $14.59M | $44.04M | $43.09M | $42.5M | $27.67M | — | — | — | |
| USD/shares | — | — | $0.03 | -$4.83 | -$1.23 | -$3.11 | $4.86 | $4.16 | $4.90 | $1.41 | $3.50 | $3.90 | $2.84 | $1.72 | $2.75 | $2.90 | $3.23 | $2.20 | $1.70 | $1.72 | $1.62 |
| USD/shares | $2.89 – $3.29 | — | $0.03G | -$4.83G | -$1.23G | -$3.11G | $4.74 | $4.02 | $4.69 | $1.33 | $3.29 | $3.66 | $2.73 | $1.68 | $2.65 | $2.80 | $3.15 | $2.16 | $1.67 | $1.67 | $1.51 |
| shares | — | — | 24.64M | 24.39M | 24.09M | 23.87M | 21.21M | 20.91M | 20.63M | 20.39M | 19.61M | 16.17M | 15.85M | 15.28M | 14.69M | 14.22M | 13.84M | 13.61M | 14.72M | 14.14M | 14.28M |
| shares | — | — | 24.9M | 24.39M | 24.09M | 23.87M | 21.78M | 21.59M | 21.55M | 21.6M | 20.86M | 17.25M | 16.5M | 15.65M | 15.27M | 14.73M | 14.16M | 13.86M | 14.98M | 14.57M | 15.27M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $226.68M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.54×
Peer median 3.63×
EV/EBIT
76.19×
Peer median 34.00×
P/E (TTM)
153.14×
Peer median 34.38×
Peer medians compare against the 24 similar-size Medical Instruments & Supplies companies (of 46 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $1,356,114,000 | $1,532,104,000 | $1,440,017,000 | $1,460,069,000 | $941,809,000 | $910,627,000 | $923,342,000 | $1,054,681,000 |
| EMEA | $411,684,000 | $393,530,000 | $373,571,000 | $367,411,000 | $147,488,000 | $132,763,000 | $130,530,000 | $134,363,000 |
| APAC Domain | $232,903,000 | $232,820,000 | $241,699,000 | $257,208,000 | $85,692,000 | $79,610,000 | — | — |
| Other Foreign Countries | $230,561,000 | $223,592,000 | $203,839,000 | $195,309,000 | $141,319,000 | $148,004,000 | $212,336,000 | $210,996,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Infusion Consumables | $1,109,130,000 | $1,038,869,000 | $969,129,000 | $974,993,000 | $555,189,000 | $473,740,000 | $477,611,000 | $483,039,000 |
| Infusion Systems | $684,208,000 | $652,410,000 | $629,043,000 | $617,435,000 | $352,321,000 | $359,691,000 | $328,282,000 | $355,484,000 |
| Vital Care | $437,924,000 | $690,767,000 | $660,954,000 | $687,569,000 | $408,798,000 | $0 | — | — |
| Critical Care | — | — | — | — | — | $48,602,000 | $45,344,000 | $53,532,000 |
| Infusion Consumables Smiths Medical | — | — | — | — | — | $0 | — | — |
| IV Solutions | — | — | — | — | — | $388,971,000 | $414,971,000 | $507,985,000 |
| Vascular Access | — | — | — | — | — | $0 | — | — |
Key facts
CIK
883984
CUSIP
44930G107
13F (30d)
238 filings
237 filers
Visit website
Investor relations